{"bundle_type":"pith_open_graph_bundle","bundle_version":"1.0","pith_number":"pith:2016:6MM4P2JTCAFYYK6XVB2RDX2FOY","short_pith_number":"pith:6MM4P2JT","canonical_record":{"source":{"id":"1603.00895","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"math.OC","submitted_at":"2016-03-02T21:24:40Z","cross_cats_sorted":[],"title_canon_sha256":"354f6570fcef19b5a5bfe23465548034f2467a47d39e76fef43f97e6dd674580","abstract_canon_sha256":"207de13792d3e665606aa480f7756bc5751825831de71bbff2aee532798c4ad1"},"schema_version":"1.0"},"canonical_sha256":"f319c7e933100b8c2bd7a87511df45761534099fa2119ac2ca88cbe28066df9f","source":{"kind":"arxiv","id":"1603.00895","version":1},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1603.00895","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"arxiv_version","alias_value":"1603.00895v1","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1603.00895","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"pith_short_12","alias_value":"6MM4P2JTCAFY","created_at":"2026-05-18T12:30:01Z"},{"alias_kind":"pith_short_16","alias_value":"6MM4P2JTCAFYYK6X","created_at":"2026-05-18T12:30:01Z"},{"alias_kind":"pith_short_8","alias_value":"6MM4P2JT","created_at":"2026-05-18T12:30:01Z"}],"events":[{"event_type":"record_created","subject_pith_number":"pith:2016:6MM4P2JTCAFYYK6XVB2RDX2FOY","target":"record","payload":{"canonical_record":{"source":{"id":"1603.00895","kind":"arxiv","version":1},"metadata":{"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"math.OC","submitted_at":"2016-03-02T21:24:40Z","cross_cats_sorted":[],"title_canon_sha256":"354f6570fcef19b5a5bfe23465548034f2467a47d39e76fef43f97e6dd674580","abstract_canon_sha256":"207de13792d3e665606aa480f7756bc5751825831de71bbff2aee532798c4ad1"},"schema_version":"1.0"},"canonical_sha256":"f319c7e933100b8c2bd7a87511df45761534099fa2119ac2ca88cbe28066df9f","receipt":{"kind":"pith_receipt","key_id":"pith-v1-2026-05","algorithm":"ed25519","signed_at":"2026-05-18T01:19:40.144679Z","signature_b64":"vvdJbgDO5cwQUFAdIgKkRUlXmr7cJ54HQmFcmIUAQv/kcO2kPOnhDIjtPlcrmA3KJmQPCxryTn1aNTlTGxQ4BQ==","signed_message":"canonical_sha256_bytes","builder_version":"pith-number-builder-2026-05-17-v1","receipt_version":"0.3","canonical_sha256":"f319c7e933100b8c2bd7a87511df45761534099fa2119ac2ca88cbe28066df9f","last_reissued_at":"2026-05-18T01:19:40.144005Z","signature_status":"signed_v1","first_computed_at":"2026-05-18T01:19:40.144005Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"source_kind":"arxiv","source_id":"1603.00895","source_version":1,"attestation_state":"computed"},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:19:40Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"ueUGZ+QFcOslacFOI89h6cTtyJDtUpAQfZtI+/qnKJw711IS2nytauVeQt6/vCbRGO3phunKOzFd1OL61oGwCw==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-01T16:07:26.300873Z"},"content_sha256":"9bbd46da3ed1975d16f3ec8bf6f99ac22665bc91bfc8dee98de7ba4bdc696118","schema_version":"1.0","event_id":"sha256:9bbd46da3ed1975d16f3ec8bf6f99ac22665bc91bfc8dee98de7ba4bdc696118"},{"event_type":"graph_snapshot","subject_pith_number":"pith:2016:6MM4P2JTCAFYYK6XVB2RDX2FOY","target":"graph","payload":{"graph_snapshot":{"paper":{"title":"Personalized Cancer Therapy Design: Robustness vs. Optimality","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","headline":"","cross_cats":[],"primary_cat":"math.OC","authors_text":"Christos G. Cassandras, Julia L. Fleck","submitted_at":"2016-03-02T21:24:40Z","abstract_excerpt":"Intermittent Androgen Suppression (IAS) is a treatment strategy for delaying or even preventing time to relapse of advanced prostate cancer. IAS consists of alternating cycles of therapy (in the form of androgen suppression) and off-treatment periods. The level of prostate specific antigen (PSA) in a patient's serum is frequently monitored to determine when the patient will be taken off therapy and when therapy will resume. In spite of extensive recent clinical experience with IAS, the design of an ideal protocol for any given patient remains one of the main challenges associated with effectiv"},"claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1603.00895","kind":"arxiv","version":1},"verdict":{"id":null,"model_set":{},"created_at":null,"strongest_claim":"","one_line_summary":"","pipeline_version":null,"weakest_assumption":"","pith_extraction_headline":""},"references":{"count":0,"sample":[],"resolved_work":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","internal_anchors":0},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"author_claims":{"count":0,"strong_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"builder_version":"pith-number-builder-2026-05-17-v1"},"verdict_id":null},"signer":{"signer_id":"pith.science","signer_type":"pith_registry","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54"},"created_at":"2026-05-18T01:19:40Z","supersedes":[],"prev_event":null,"signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"B7/mjPHUgD7DGi47RRUowoALo0VVZ1kkXXaxoTa3C4DqQQbW4EfzyDoFNiCBTS7yM3NmYg6z5Nl1aMZYiiD9AQ==","signed_message":"open_graph_event_sha256_bytes","signed_at":"2026-07-01T16:07:26.301226Z"},"content_sha256":"a416fa042104e4003e8499e1148cb5eefef7b9e34e9375c0e6caa305eae3311f","schema_version":"1.0","event_id":"sha256:a416fa042104e4003e8499e1148cb5eefef7b9e34e9375c0e6caa305eae3311f"}],"timestamp_proofs":[],"mirror_hints":[{"mirror_type":"https","name":"Pith Resolver","base_url":"https://pith.science","bundle_url":"https://pith.science/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/bundle.json","state_url":"https://pith.science/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/state.json","well_known_bundle_url":"https://pith.science/.well-known/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/bundle.json","status":"primary"}],"public_keys":[{"key_id":"pith-v1-2026-05","algorithm":"ed25519","format":"raw","public_key_b64":"stVStoiQhXFxp4s2pdzPNoqVNBMojDU/fJ2db5S3CbM=","public_key_hex":"b2d552b68890857171a78b36a5dccf368a953413288c353f7c9d9d6f94b709b3","fingerprint_sha256_b32_first128bits":"RVFV5Z2OI2J3ZUO7ERDEBCYNKS","fingerprint_sha256_hex":"8d4b5ee74e4693bcd1df2446408b0d54","rotates_at":null,"url":"https://pith.science/pith-signing-key.json","notes":"Pith uses this Ed25519 key to sign canonical record SHA-256 digests. Verify with: ed25519_verify(public_key, message=canonical_sha256_bytes, signature=base64decode(signature_b64))."}],"merge_version":"pith-open-graph-merge-v1","built_at":"2026-07-01T16:07:26Z","links":{"resolver":"https://pith.science/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY","bundle":"https://pith.science/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/bundle.json","state":"https://pith.science/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/state.json","well_known_bundle":"https://pith.science/.well-known/pith/6MM4P2JTCAFYYK6XVB2RDX2FOY/bundle.json"},"state":{"state_type":"pith_open_graph_state","state_version":"1.0","pith_number":"pith:2016:6MM4P2JTCAFYYK6XVB2RDX2FOY","merge_version":"pith-open-graph-merge-v1","event_count":2,"valid_event_count":2,"invalid_event_count":0,"equivocation_count":0,"current":{"canonical_record":{"metadata":{"abstract_canon_sha256":"207de13792d3e665606aa480f7756bc5751825831de71bbff2aee532798c4ad1","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"math.OC","submitted_at":"2016-03-02T21:24:40Z","title_canon_sha256":"354f6570fcef19b5a5bfe23465548034f2467a47d39e76fef43f97e6dd674580"},"schema_version":"1.0","source":{"id":"1603.00895","kind":"arxiv","version":1}},"source_aliases":[{"alias_kind":"arxiv","alias_value":"1603.00895","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"arxiv_version","alias_value":"1603.00895v1","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"doi","alias_value":"10.48550/arxiv.1603.00895","created_at":"2026-05-18T01:19:40Z"},{"alias_kind":"pith_short_12","alias_value":"6MM4P2JTCAFY","created_at":"2026-05-18T12:30:01Z"},{"alias_kind":"pith_short_16","alias_value":"6MM4P2JTCAFYYK6X","created_at":"2026-05-18T12:30:01Z"},{"alias_kind":"pith_short_8","alias_value":"6MM4P2JT","created_at":"2026-05-18T12:30:01Z"}],"graph_snapshots":[{"event_id":"sha256:a416fa042104e4003e8499e1148cb5eefef7b9e34e9375c0e6caa305eae3311f","target":"graph","created_at":"2026-05-18T01:19:40Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"graph_snapshot":{"author_claims":{"count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57","strong_count":0},"builder_version":"pith-number-builder-2026-05-17-v1","claims":{"count":0,"items":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"formal_canon":{"evidence_count":0,"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"paper":{"abstract_excerpt":"Intermittent Androgen Suppression (IAS) is a treatment strategy for delaying or even preventing time to relapse of advanced prostate cancer. IAS consists of alternating cycles of therapy (in the form of androgen suppression) and off-treatment periods. The level of prostate specific antigen (PSA) in a patient's serum is frequently monitored to determine when the patient will be taken off therapy and when therapy will resume. In spite of extensive recent clinical experience with IAS, the design of an ideal protocol for any given patient remains one of the main challenges associated with effectiv","authors_text":"Christos G. Cassandras, Julia L. Fleck","cross_cats":[],"headline":"","license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"math.OC","submitted_at":"2016-03-02T21:24:40Z","title":"Personalized Cancer Therapy Design: Robustness vs. Optimality"},"references":{"count":0,"internal_anchors":0,"resolved_work":0,"sample":[],"snapshot_sha256":"258153158e38e3291e3d48162225fcdb2d5a3ed65a07baac614ab91432fd4f57"},"source":{"id":"1603.00895","kind":"arxiv","version":1},"verdict":{"created_at":null,"id":null,"model_set":{},"one_line_summary":"","pipeline_version":null,"pith_extraction_headline":"","strongest_claim":"","weakest_assumption":""}},"verdict_id":null}}],"author_attestations":[],"timestamp_anchors":[],"storage_attestations":[],"citation_signatures":[],"replication_records":[],"corrections":[],"mirror_hints":[],"record_created":{"event_id":"sha256:9bbd46da3ed1975d16f3ec8bf6f99ac22665bc91bfc8dee98de7ba4bdc696118","target":"record","created_at":"2026-05-18T01:19:40Z","signer":{"key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signer_id":"pith.science","signer_type":"pith_registry"},"payload":{"attestation_state":"computed","canonical_record":{"metadata":{"abstract_canon_sha256":"207de13792d3e665606aa480f7756bc5751825831de71bbff2aee532798c4ad1","cross_cats_sorted":[],"license":"http://arxiv.org/licenses/nonexclusive-distrib/1.0/","primary_cat":"math.OC","submitted_at":"2016-03-02T21:24:40Z","title_canon_sha256":"354f6570fcef19b5a5bfe23465548034f2467a47d39e76fef43f97e6dd674580"},"schema_version":"1.0","source":{"id":"1603.00895","kind":"arxiv","version":1}},"canonical_sha256":"f319c7e933100b8c2bd7a87511df45761534099fa2119ac2ca88cbe28066df9f","receipt":{"algorithm":"ed25519","builder_version":"pith-number-builder-2026-05-17-v1","canonical_sha256":"f319c7e933100b8c2bd7a87511df45761534099fa2119ac2ca88cbe28066df9f","first_computed_at":"2026-05-18T01:19:40.144005Z","key_id":"pith-v1-2026-05","kind":"pith_receipt","last_reissued_at":"2026-05-18T01:19:40.144005Z","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","receipt_version":"0.3","signature_b64":"vvdJbgDO5cwQUFAdIgKkRUlXmr7cJ54HQmFcmIUAQv/kcO2kPOnhDIjtPlcrmA3KJmQPCxryTn1aNTlTGxQ4BQ==","signature_status":"signed_v1","signed_at":"2026-05-18T01:19:40.144679Z","signed_message":"canonical_sha256_bytes"},"source_id":"1603.00895","source_kind":"arxiv","source_version":1}}},"equivocations":[],"invalid_events":[],"applied_event_ids":["sha256:9bbd46da3ed1975d16f3ec8bf6f99ac22665bc91bfc8dee98de7ba4bdc696118","sha256:a416fa042104e4003e8499e1148cb5eefef7b9e34e9375c0e6caa305eae3311f"],"state_sha256":"839a55b430ebd79d0867e64effc53f148a5962665cca82489116d1f3be22da70"},"bundle_signature":{"signature_status":"signed_v1","algorithm":"ed25519","key_id":"pith-v1-2026-05","public_key_fingerprint":"8d4b5ee74e4693bcd1df2446408b0d54","signature_b64":"MsYlqHZL0qmaO0dGM48ORYVJQfeLXlgoIbMPkLfsULD4AcS2btJirHdUfvRAhkW2x2o0P4gzTKq6pTaR9M2pAQ==","signed_message":"bundle_sha256_bytes","signed_at":"2026-07-01T16:07:26.303213Z","bundle_sha256":"ce3b742af0b7bef2d37ef9ce0aa01134110a77cd488ba729bbc2bf334485ccfc"}}